Novartis and Intercell AG have formed a strategic alliance for the development of vaccines. The alliance combines Novartis’ research, development, manufacturing and commercialization capabilities with Intercell’s research skills and pipeline. Intercell’s portfolio includes more than 10 projects for which Novartis may choose for further development, including the IC43 vaccine candidate for hospital-acquired pseudomonas infections, currently in Phase II trials, and the prec...